Cefpodoxime Proxetil for Oral Suspension Rx
Generic Name and Formulations:
Cefpodoxime proxetil 50mg/5mL, 100mg/5mL; for oral susp; lemon-creme flavor.
Various generic manufacturers
Indications for Cefpodoxime Proxetil for Oral Suspension:
Susceptible mild to moderate infections including acute otitis media, acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, acute community-acquired pneumonia, urinary tract, skin and skin structures; cervical, anorectal (females only) and urethral gonorrhea.
Take tabs with food. ≥13yrs: Pneumonia: 200mg every 12hrs for 14 days. Bronchitis, sinusitis: 200mg every 12hrs for 10 days. Pharyngitis/tonsillitis: 100mg every 12hrs for 5–10 days. Skin and skin structures: 400mg every 12hrs for 7–14 days. UTI: 100mg every 12hrs for 7 days. Uncomplicated gonorrhea: 200mg once as a single dose. Renal failure or hemodialysis: see full labeling.
Use susp. <2 months: not recommended. 2 months–12yrs: Acute otitis media: 5mg/kg (max 200mg) every 12hrs for 5 days. Pharyngitis/tonsillitis: 5mg/kg (max 100mg) every 12hrs for 5–10 days. Sinusitis: 5mg/kg (max 200mg) every 12hrs for 10 days.
Penicillin or other allergy. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: not recommended.
Antacids, H2 antagonists, oral anticholinergics may decrease efficacy. Potentiated by probenecid. Avoid concomitant diuretics, other nephrotoxic drugs. May cause false (+) direct Coomb's test.
GI upset, abdominal pain, headache, rash, anaphylaxis.
Formerly known under the brand name Vantin.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency